Taysha Gene Therapies Debt to Equity Ratio 2020-2024 | TSHA

Current and historical debt to equity ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Taysha Gene Therapies debt/equity for the three months ending September 30, 2024 was 0.48.
Taysha Gene Therapies Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-09-30 $0.09B $0.09B 1.03
2024-06-30 $0.09B $0.11B 0.84
2024-03-31 $0.10B $0.05B 1.84
2023-12-31 $0.10B $0.08B 1.31
2023-09-30 $0.25B $-0.05B -4.99
2023-06-30 $0.12B $-0.04B -3.20
2023-03-31 $0.12B $-0.02B -7.80
2022-12-31 $0.13B $0.00B 132.06
2022-09-30 $0.10B $0.01B 9.02
2022-06-30 $0.11B $0.03B 3.35
2022-03-31 $0.12B $0.05B 2.27
2021-12-31 $0.12B $0.10B 1.24
2021-09-30 $0.10B $0.14B 0.72
2021-06-30 $0.06B $0.19B 0.30
2021-03-31 $0.02B $0.22B 0.09
2020-12-31 $0.01B $0.25B 0.03
2020-09-30 $0.01B $0.27B 0.04
2020-06-30 $0.00B $0.00B 0.00
2020-03-31 $0.00B $0.00B 0.00
2019-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.434B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00